当前位置: 首页 >> 检索结果
241. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.
作者: Henriette Kreimeyer.;Carlos G Gonzalez.;Marcos F Fondevila.;Cynthia L Hsu.;Phillipp Hartmann.;Xinlian Zhang.;Peter Stärkel.;Francisco Bosques-Padilla.;Elizabeth C Verna.;Juan G Abraldes.;Robert S Brown.;Victor Vargas.;Jose Altamirano.;Juan Caballería.;Debbie L Shawcross.;Alexandre Louvet.;Michael R Lucey.;Philippe Mathurin.;Guadalupe Garcia-Tsao.;Ramón Bataller.;AlcHepNet Investigators.;David J Gonzalez.;Bernd Schnabl.
来源: Gut. 2024年74卷1期103-115页
Patients with alcohol-associated hepatitis (AH) have a high mortality. Alcohol exacerbates liver damage by inducing gut dysbiosis, bacterial translocation and inflammation, which is characterised by increased numbers of circulating and hepatic neutrophils.
245. Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed. This article discusses novel cellular immunotherapies and immune cell depleting therapies in IBD, including CAR-T cell approaches, Tr1 and T regulatory (Treg) cells and cell depleting antibodies such as rosnilimab. These novel approaches have the potential to overcome current therapeutic limitations in the treatment of IBD.
247. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis.
作者: Serena Porcari.;Maria Rosa Ingrosso.;Marcello Maida.;Leonardo Henry Eusebi.;Christopher Black.;Antonio Gasbarrini.;Giovanni Cammarota.;Alexander Charles Ford.;Gianluca Ianiro.
来源: Gut. 2024年73卷9期1431-1440页
Disorders of gut-brain interaction may arise after acute gastroenteritis. Data on the influence of pathogen type on the risk of postinfection IBS (PI-IBS), as on postinfection functional dyspepsia (PI-FD), are limited. We conducted a systematic review and meta-analysis to determine prevalence of PI-IBS or PI-FD after acute gastroenteritis.
248. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
作者: Arnau Vich Vila.;Jingwan Zhang.;Moting Liu.;Klaas Nico Faber.;Rinse K Weersma.
来源: Gut. 2024年73卷11期1909-1920页
The gut microbiome has been recognised as a key component in the pathogenesis of inflammatory bowel diseases (IBD), and the wide range of metabolites produced by gut bacteria are an important mechanism by which the human microbiome interacts with host immunity or host metabolism. High-throughput metabolomic profiling and novel computational approaches now allow for comprehensive assessment of thousands of metabolites in diverse biomaterials, including faecal samples. Several groups of metabolites, including short-chain fatty acids, tryptophan metabolites and bile acids, have been associated with IBD. In this Recent Advances article, we describe the contribution of metabolomics research to the field of IBD, with a focus on faecal metabolomics. We discuss the latest findings on the significance of these metabolites for IBD prognosis and therapeutic interventions and offer insights into the future directions of metabolomics research.
249. Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+ myeloid cells to promote liver cancer progression.
作者: Yang Yang.;Tianduo Pei.;Chaobao Liu.;Mingtao Cao.;Xiaolin Hu.;Jie Yuan.;Fengqian Chen.;Bao Guo.;Yuemei Hong.;Jibin Liu.;Bin Li.;Xiaoguang Li.;Hui Wang.
来源: Gut. 2025年74卷2期255-269页
The metabolic characteristics of liver cancer drive considerable hurdles to immune cells function and cancer immunotherapy. However, how metabolic reprograming in the tumour microenvironment impairs the antitumour immune response remains unclear.
252. KLHL21 suppresses gastric tumourigenesis via maintaining STAT3 signalling equilibrium in stomach homoeostasis.
作者: Xiao-Bo Huang.;Qiang Huang.;Mei-Chen Jiang.;Qing Zhong.;Hua-Long Zheng.;Jia-Bin Wang.;Ze-Ning Huang.;Hua-Gen Wang.;Zhi-Yu Liu.;Yi-Fan Li.;Kai-Xiang Xu.;Mi Lin.;Ping Li.;Zhi-Hong Huang.;Jian-Wei Xie.;Jian-Xian Lin.;Jun Lu.;Jian-Wen Que.;Chao-Hui Zheng.;Qi-Yue Chen.;Chang-Ming Huang.
来源: Gut. 2024年73卷11期1785-1798页
Precancerous metaplasia transition to dysplasia poses a risk for subsequent intestinal-type gastric adenocarcinoma. However, the molecular basis underlying the transformation from metaplastic to cancerous cells remains poorly understood.
253. Dysregulated KLF4 expression plays a pivotal role in the pathogenesis of pancreatic intraductal papillary mucinous neoplasms.
作者: Xiangsheng Zuo.;Liang Wang.;Yi Liu.;Huamin Wang.;Margarete Hafley.;Mihai Gagea.;Ru Chen.;Yun Xiong.;Sheng Pan.;Imad Shureiqi.;Robert S Bresalier.;Daoyan Wei.
来源: Gut. 2025年74卷2期327-329页 256. Cold versus hot snare endoscopic mucosal resection for large (≥15 mm) flat non-pedunculated colorectal polyps: a randomised controlled trial.
作者: Timothy O'Sullivan.;Oliver Cronin.;W Arnout van Hattem.;Francesco Vito Mandarino.;Julia L Gauci.;Clarence Kerrison.;Anthony Whitfield.;Sunil Gupta.;Eric Lee.;Stephen J Williams.;Nicholas Burgess.;Michael J Bourke.
来源: Gut. 2024年73卷11期1823-1830页
Conventional hot snare endoscopic mucosal resection (H-EMR) is effective for the management of large (≥20 mm) non-pedunculated colon polyps (LNPCPs) however, electrocautery-related complications may incur significant morbidity. With a superior safety profile, cold snare EMR (C-EMR) of LNPCPs is an attractive alternative however evidence is lacking. We conducted a randomised trial to compare the efficacy and safety of C-EMR to H-EMR.
258. Integrated metagenomic and metabolomic analysis reveals distinctive stage-specific gut-microbiome-derived metabolites in intracranial aneurysms.
作者: Haitao Sun.;Kaijian Sun.;Hao Tian.;Xiheng Chen.;Shixing Su.;Yi Tu.;Shilan Chen.;Jiaxuan Wang.;Meichang Peng.;Meiqin Zeng.;Xin Li.;Yunhao Luo.;Yugu Xie.;Xin Feng.;Zhuang Li.;Xin Zhang.;Xifeng Li.;Yanchao Liu.;Wei Ye.;Zhengrui Chen.;Zhaohua Zhu.;Youxiang Li.;Fangbo Xia.;Hongwei Zhou.;Chuanzhi Duan.
来源: Gut. 2024年73卷10期1662-1674页
Our study aimed to explore the influence of gut microbiota and their metabolites on intracranial aneurysms (IA) progression and pinpoint-related metabolic biomarkers derived from the gut microbiome.
259. Pancreatic STAT5 activation promotes KrasG12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer.
作者: Yuli Lin.;Shaofeng Pu.;Jun Wang.;Yaqi Wan.;Zhihao Wu.;Yangyang Guo.;Wenxue Feng.;Ying Ying.;Shuai Ma.;Xiang Jun Meng.;Wenquan Wang.;Liang Liu.;Qing Xia.;Xuguang Yang.
来源: Gut. 2024年73卷11期1831-1843页
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy because it is often diagnosed at a late-stage. Signal transducer and activator of transcription 5 (STAT5) is a transcription factor implicated in the progression of various cancer types. However, its role in KRAS-driven pancreatic tumourigenesis remains unclear.
260. Multiple indicators of gut dysbiosis predict all-cause and cause-specific mortality in solid organ transplant recipients.
作者: J Casper Swarte.;Shuyan Zhang.;Lianne M Nieuwenhuis.;Ranko Gacesa.;Tim J Knobbe.; .;Vincent E De Meijer.;Kevin Damman.;Erik A M Verschuuren.;Tji C Gan.;Jingyuan Fu.;Alexandra Zhernakova.;Hermie J M Harmsen.;Hans Blokzijl.;Stephan J L Bakker.;Johannes R Björk.;Rinse K Weersma.; .
来源: Gut. 2024年73卷10期1650-1661页
Gut microbiome composition is associated with multiple diseases, but relatively little is known about its relationship with long-term outcome measures. While gut dysbiosis has been linked to mortality risk in the general population, the relationship with overall survival in specific diseases has not been extensively studied. In the current study, we present results from an in-depth analysis of the relationship between gut dysbiosis and all-cause and cause-specific mortality in the setting of solid organ transplant recipients (SOTR).
|